KRT-232 and TKI Study in Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia Interventions: Drug: KRT-232; Drug: Dasatinib; Drug: Nilotinib Sponsor: Kartos Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Nilotinib | Research | Study | Tasigna